VRCA Verrica Pharmaceuticals Inc.
Healthcare$6.02-0.66%ClosedMarket Cap: $64.1M
As of 2026-05-26
Valuation
P/E (TTM)
—
PEG
—
P/B
4.02
P/S
1.74
EV/EBITDA
-3.93
DCF Value
$-21.84
FCF Yield
-21.9%
Div Yield
0.0%
Margins & Returns
Gross Margin
89.5%
Operating Margin
-36.4%
Net Margin
-48.0%
ROE
-1136.5%
ROA
-46.0%
ROIC
-58.0%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $5.0M | 82.3% | $-9.7M | $-9.7M | $— | — |
| Q4 null | $5.1M | 72.5% | $-6.9M | $-8.1M | $— | — |
| FY null | $35.6M | 90.3% | $-11.9M | $-17.9M | $— | — |
| Q3 null | $14.3M | 92.3% | $1.6M | $-274.0K | $— | — |
| Q2 null | $12.7M | 96.1% | $1.5M | $204.0K | $— | — |
| Q1 null | $3.4M | 87.7% | $-8.1M | $-9.7M | $— | — |
| Q4 null | $344.0K | -81.7% | $-11.4M | $-16.2M | $— | — |
| FY null | $7.6M | 63.8% | $-65.9M | $-76.6M | $— | — |
| Q3 null | $-1.8M | 124.4% | $-20.7M | $-22.9M | $— | — |
| Q2 null | $5.2M | 89.5% | $-15.2M | $-17.2M | $— | — |
| Q1 null | $3.8M | 70.3% | $-18.6M | $-20.3M | $— | — |
| Q4 2023 | $2.0M | -934.6% | $-23.1M | $-24.6M | $-5.31 | — |